Excelra Releases COVID-19 Drug Repurposing Database to Support Global Drug Development Efforts Against Novel Coronavirus

Excelra Knowledge Solutions Pvt Ltd

PR83631

 

HYDERABAD, India, April 9, 2020 /PRNewswire=KYODO JBN/ --

 

Excelra, a leading global data and analytics company, today announced the

release of the COVID-19 Drug Repurposing Database

(https://www.excelra.com/covid-19-drug-repurposing-database/). The

'open-access' database presents a compilation of 'previously approved' small

molecules and biologics with known preclinical, pharmacokinetic,

pharmacodynamic, and toxicity profiles that can rapidly enter either Phase 2 or

3 clinical trials on fast track basis for COVID-19. In addition, the database

also includes information on promising drug candidates that are in various

'clinical, pre-clinical and experimental' stages of drug discovery and

development for COVID-19.

 

Alluding to this wealth of information, Dr. Nandu Gattu, Senior Vice

President, Pharma Analytics, Excelra said, "The COVID-19 DR database is a

compilation of crucial data that is dispersed across numerous publications,

reports, databases and knowledge-repositories along with referenced literature

covering the drug, disease, target, and mechanism of action. Our endeavour is

in support to the ongoing global scientific efforts for identifying safe and

effective therapeutic options to treat the novel coronavirus disease."

 

Drug Repurposing at Excelra is powered by their Global Repurposing

Integrated Platform (GRIP) that combines proprietary repurposing databases,

algorithms, analytics tools and a visualization engine. The GRIP database is

built by amassing vast chemical data, biological data and clinical data which

together contribute to more than 10 million associations among

'drug-disease-target' triads.

https://www.excelra.com/translational/#drug_repositioning

 

About Excelra:

 

Excelra's data and analytics solutions empower innovation in life sciences

across the value chain from discovery to market. The Excelra Edge comes from a

seamless amalgamation of proprietary curated data assets, deep domain expertise

and data science. The company's multifaceted teams harmonize and analyse large

volumes of disparate unstructured data using cutting-edge technologies. We

galvanize data-driven decisions to unlock operational efficiencies to

accelerate drug discovery and development. Over the past 18 years, Excelra has

been the preferred data and analytics partner to over 150 global clients

including 15 of the top 20 large Pharma companies.

www.excelra.com

 

Access COVID-19 Drug Repurposing Database:

https://www.excelra.com/covid-19-drug-repurposing-database/

 

Contact Information:

Dorothy Paul – Director Marketing

Tel: +91-9908130236

Email: dorothy.paul@excelra.com

 

Logo: https://mma.prnewswire.com/media/692189/Excelra_Logo.jpg

 

Source: Excelra Knowledge Solutions Pvt Ltd

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中